Core Insights - iBio, Inc. is hosting a corporate update call on March 17, 2026, to discuss its strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) [1] - The company is developing a selective bispecific antibody targeting Activin A, GDF8 (myostatin), and GDF11 to address cardiac fibrosis and improve functional capacity, filling a gap in current PH-HFpEF therapies [2][3] - iBio aims to declare its optimized bispecific antibody development candidate for PH-HFpEF in Q3 2026, prior to entering IND-enabling activities [2] Company Overview - iBio, Inc. is a biotech company utilizing AI and advanced computational biology to create biopharmaceuticals for cardiometabolic and cardiopulmonary diseases, among others [7] - The company focuses on developing breakthrough antibody treatments to meet significant unmet medical needs, particularly in cardiometabolic diseases [7] Disease Context - Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome affecting approximately half of all heart failure cases, often linked to obesity, diabetes, hypertension, and aging [5] - PH-HFpEF is a severe subtype associated with pulmonary vascular remodeling and poor prognosis, highlighting the need for more effective treatments [5] Bispecific Antibody Program - iBio's bispecific antibody program targets myostatin (GDF8), GDF11, and Activin A, which are crucial for skeletal muscle health and metabolic function, potentially addressing both obesity-related dysfunction and PH-HFpEF [6]

Summary of iBio Conference Call Company Overview - **Company**: iBio (NYSEAM:IBIO) - **Industry**: Biotechnology, specifically focusing on cardiometabolic diseases and obesity treatments Key Points and Arguments Long-term Vision - iBio pivoted into the cardiometabolic space two years ago, focusing on treatments that follow GLP-1s, which are becoming a cornerstone in obesity treatment. The company aims to address unmet needs in patient care within this space [7][8] Value Inflection Points - Upcoming milestones include: - External data from Wave and Arrowhead - Filing for Activin E by the end of the year, with potential interim data by the end of next year - Progress on bispecific myostatin activin A program, expected to enter the clinic in the second half of next year - Myostatin program acceptance in Australia, with first patient dosing anticipated in Q3 [12][12][12] IBIO-610 (Activin E Antibody) - The antibody targets the Activin E pathway at the protein level in blood, differentiating it from competitors focusing on gene-level interventions [25] - Aiming for near-complete inhibition of the pathway, which may lead to better efficacy compared to competitors [26] - Safety profile is expected to be favorable due to the extensive history of antibody use [29] - Designed for long-acting subcutaneous administration, with a half-life of approximately 100 days in humans [33] Competitive Landscape - iBio is learning from competitors' data on visceral fat and liver fat reductions, which may inform their trial designs and patient populations [35][36] - The company is particularly interested in inflammation biomarkers, which could link to cardiovascular disease protection [40][41] Regulatory Considerations - The company is cautious about regulatory pathways, emphasizing the need for endpoints that reflect real patient benefits rather than just weight loss [44][45] Patient Populations - Targeting a broad range of patients, including those with type 2 diabetes, liver fibrosis, and obstructive sleep apnea [51][52] - The potential for the drug to address weight maintenance in obesity is highlighted as a significant unmet need [49] Pipeline and Future Indications - iBio is developing a bispecific antibody targeting myostatin, GDF11, and activin A, which may address multi-organ diseases like heart failure with preserved ejection fraction [58][59] - The company is not focused on rare diseases but is open to partnerships for those indications [62] Financial Overview - iBio has cash reserves extending into Q1 2028, prioritizing the development of Activin E, bispecific, and myostatin programs [71] - Current market cap is approximately $350 million, with a fully diluted cap closer to $500 million [71] Partnership Strategy - iBio is considering partnerships for larger indications like obesity, while smaller indications may be developed independently [73] - The company is selective in partnerships, aiming to maximize shareholder value [74] Underappreciated Aspects - The team, platform, and persistence are highlighted as key strengths that differentiate iBio in the competitive landscape [77] Additional Important Content - The integration of AI in drug discovery is emphasized, allowing for the development of more effective and manufacturable antibodies [66][68] - The company is focused on optimizing both antibodies and antigens, which sets it apart from competitors [67][68]

BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION March 2026 Forward looking statements Certain statements in this presentation constitute "forward -looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, be ...

Core Insights - iBio, Inc. announced promising preclinical data for its Activin E antibody candidate, IBIO-610, showing a reduction of 6.7% in visceral fat and 5.2% in total fat mass in obese non-human primates despite a high-calorie diet [1][2][3] Group 1: Study Findings - The preclinical study demonstrated that IBIO-610 significantly reduced fat mass in obese non-human primates compared to vehicle-treated controls, although the study was small and not statistically powered [2] - Following two doses administered every eight weeks, the treatment resulted in a slight increase in lean mass, indicating a fat-selective profile consistent with previous rodent studies and human clinical trials targeting the Activin E pathway [2][4] Group 2: Therapeutic Potential - The results support the continued evaluation of IBIO-610 as a differentiated therapy for obesity, cardiometabolic, and cardiopulmonary diseases, with the potential to improve patient outcomes [2][3] - iBio's CEO highlighted the extended half-life of IBIO-610, reported at 33.2 days in non-human primates and projected to be up to 100 days in humans, suggesting the possibility of convenient dosing schedules [3] Group 3: Company Overview - iBio, Inc. is a biotech company focused on developing next-generation biopharmaceuticals for challenging diseases, leveraging AI and advanced computational biology to create innovative therapies [5] - The company aims to transform drug discovery and accelerate development timelines, addressing significant unmet medical needs in the fields of cardiometabolic, obesity, and cardiopulmonary diseases [5]

iBio Conference Call Summary Company Overview - **Company**: iBio (NYSEAM:IBIO) - **Event**: FY Conference on February 26, 2026 - **Speakers**: Martin Brenner (CEO and CSO), Felipe Duran (CFO) Industry Insights - **Focus Area**: Obesity treatment and related therapies - **Key Drug Class**: GLP-1 (Glucagon-like peptide-1) drugs have shown significant efficacy in obesity treatment, previously achievable only through invasive surgery [3][4] - **Market Need**: There is a growing need for therapies that address the shortcomings of GLP-1 drugs, particularly in preventing lean mass loss and maintaining weight loss [7][9] Core Strategies and Products - **Portfolio Strategy**: iBio is focusing on second-generation drugs that address unmet patient needs beyond GLP-1s, including: - **IBIO-600**: A myostatin molecule aimed at preventing lean mass loss during weight loss [7] - **Activin E**: A long-acting molecule that targets fat-specific weight loss while preserving muscle [14][19] - **Bispecific Molecule**: Targeting myostatin and activin A for conditions like HFpEF (Heart Failure with preserved Ejection Fraction) and obesity [11][30] Clinical Development and Milestones - **Upcoming Data**: Non-human primate data for IBIO-610 expected in the next 30 to 60 days, with presentations planned at ADA ObesityWeek and the European Diabetic Association meeting [10][40] - **IND Filings**: Plans to file for IND equivalent in Australia by the second half of 2026, with first patient dosing anticipated in early 2027 [10][11] - **Clinical Trials**: Emphasis on Phase 1 studies for IBIO-610, leveraging insights from competitors like Arrowhead and Wave [42][44] Market Potential - **Obesity Statistics**: Approximately 1 billion obese individuals worldwide, with a treatable population estimated at 100 to 200 million [19][20] - **Antibody Modality**: iBio's approach to using antibodies for obesity treatment is expected to allow for scalable production and flexibility in market entry [20] Competitive Landscape - **Differentiation**: iBio aims to differentiate its products from existing therapies by focusing on mechanisms that reduce adverse effects associated with GLP-1s and other treatments [8][32] - **Market Position**: The company is positioned as a potential leader in the obesity treatment space, particularly with its unique antibody approaches [52] Financial Overview - **Market Capitalization**: iBio has a market cap of approximately $500 million, with a low float of 34.5 million shares outstanding [36] - **Funding**: The company is well-capitalized, with cash reserves expected to last until the first quarter of 2028, allowing for continued development of its assets [36] Additional Insights - **Patient Journey**: Highlighted the challenges patients face with GLP-1 treatments, including muscle loss and rapid weight regain after discontinuation [5][6] - **Regulatory Considerations**: Acknowledgment of the lack of a regulatory path for weight maintenance drugs, but optimism that high unmet medical needs will drive future decisions [9] Conclusion - iBio is strategically positioned to address significant unmet needs in obesity treatment through innovative drug development and a focus on maintaining muscle mass during weight loss. The upcoming clinical data and regulatory filings will be critical in establishing its market presence and therapeutic efficacy.

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, Fe ...

Drug Development and Clinical Trials - iBio's AI Drug Discovery Platform enables the rapid generation of antibody therapeutics characterized by high specificity and optimized developability [265]. - The company anticipates IBIO-600 will enter Phase 1a clinical trials in the first half of calendar 2026, marking a significant milestone [242]. - In preclinical studies, IBIO-610 demonstrated an 8.9% reduction in body weight and a 26% reduction in fat mass in a diet-induced obesity mouse model [251]. - The combination of IBIO-610 with semaglutide resulted in a 35.3% weight loss, compared to 27.8% with semaglutide alone [252]. - IBIO-610 exhibited a terminal half-life of approximately 33.2 days in non-human primates, with projected human half-life estimated between 47 to 100 days [254]. - The company is developing a bispecific antibody targeting both myostatin and Activin A, showing promise in enhancing muscle cell differentiation [256]. - IBIO-600 was observed to prevent lean mass loss when administered in combination with a GLP-1 receptor agonist in preclinical studies [258]. - Early preclinical results from an amylin receptor antibody program showed a ~60% reduction in acute food intake in a proof-of-concept study [264]. Financial Performance - The company reported a net loss of approximately $14.7 million for the six months ended December 31, 2025, with negative cash flows from operations of approximately $10.9 million [299]. - The company reported a net loss of $9.0 million, or $0.09 per share, for the three months ended December 31, 2025, compared to a net loss of approximately $4.4 million, or $0.48 per share, for the same period in 2024 [306]. - For the six months ended December 31, 2025, the company reported a net loss of $14.7 million, or $0.19 per share, compared to a net loss of approximately $8.4 million, or $0.94 per share, for the same period in 2024 [312]. - The accumulated deficit as of December 31, 2025, was approximately $346.9 million, up from approximately $322.2 million as of December 31, 2024 [318]. Cash and Assets - Total current assets as of December 31, 2025, were approximately $53.4 million, including approximately $28.7 million in cash and cash equivalents [299]. - As of December 31, 2025, the company's cash and cash equivalents, along with investments in debt securities, totaled approximately $52.7 million, sufficient to fund operations for at least 12 months [300]. - The company raised approximately $26 million in gross proceeds from a private placement involving the issuance of 1,408,481 shares of common stock and pre-funded warrants [293]. - The purchase price per share in the private placement was $2.35, with pre-funded warrants priced at $2.349 [292]. - Net cash provided by financing activities during the six months ended December 31, 2025, was approximately $55.5 million, primarily from a public offering that raised approximately $50 million [315]. Research and Development Expenses - Research and Development (R&D) expenses increased to $4.3 million for the three months ended December 31, 2025, up from $1.9 million in the same period of 2024, reflecting a rise of approximately 126% [303]. - General and Administrative (G&A) expenses rose to approximately $5.2 million for the three months ended December 31, 2025, compared to $2.7 million in the same period of 2024, an increase of approximately 93% [304]. - Total operating expenses for the three months ended December 31, 2025, were approximately $9.4 million, compared to approximately $4.6 million in the same period of fiscal year 2024 [305]. - The operating capital deficit for the six months ended December 31, 2025, was $10.9 million, compared to a $7.6 million deficit for the same period in 2024 [299]. Strategic Collaborations - The company has entered into a collaboration with AstralBio to develop novel antibodies for obesity and cardiometabolic diseases, granting an exclusive license for four targets [287]. - iBio's strategic approach includes pursuing selective collaborations and out-licensing opportunities to broaden the use of its AI Drug Discovery Platform [247]. - The company is exploring partnerships for its preclinical immune-oncology candidates and seeking opportunities for future collaborations using its AI Drug Discovery Platform [291]. Technology and Innovation - The proprietary StableHu technology has been trained using over 1 billion human antibodies to optimize antibody development [274]. - The EngageTx CD3-based T-cell engager panel aims to reduce cytokine release while maintaining potent tumor-killing activity [279]. - The ShieldTx platform integrates antibody masking technology to enhance safety and efficacy by activating antibodies only in diseased tissues [282].

Financing and Cash Position - iBio secured $26 million in PIPE financing to advance preclinical programs and extend cash runway into Q3 FY 2028[1][3][7] - iBio's cash, cash equivalents, and investments totaled $52.7 million as of December 31, 2025[7] Revenue and Expenses - The company reported no revenue for Q2 FY 2026, compared to $0.2 million in Q2 FY 2025[4][15] - R&D expenses increased to $4.3 million in Q2 FY 2026 from $1.9 million in Q2 FY 2025, a rise of approximately 126.3%[5][15] - General and Administrative expenses rose to $5.2 million in Q2 FY 2026 from $2.7 million in Q2 FY 2025, an increase of 92.6%[6][15] - Total operating expenses for Q2 FY 2026 were $9.4 million, compared to $4.6 million in Q2 FY 2025[15] - The net loss for Q2 FY 2026 was $8.99 million, compared to a net loss of $4.36 million in Q2 FY 2025[15] Research and Development - IBIO-610, a potential first-in-class Activin E antibody, shows a predicted human half-life of up to 100 days, supporting dosing as infrequently as twice per year[3][11] - IBIO-600 is on track to enter Phase 1a clinical trials in the first half of calendar year 2026[3][11] - The company presented new data at industry conferences, including findings on long-acting antibodies for obesity therapeutics[3][10]

Core Viewpoint - iBio, Inc. has secured $26 million in PIPE financing to advance its preclinical programs and extend its cash runway, while also reporting no revenue for the second quarter of fiscal year 2026, highlighting significant increases in R&D and G&A expenses [1][4][7]. Financial Results - The company reported no revenue for the three months ending December 31, 2025, compared to $0.2 million for the same period in 2024 [4]. - R&D expenses increased to $4.3 million for the three months ending December 31, 2025, from $1.9 million in the same period of 2024, reflecting a rise of approximately $2.4 million [4][6]. - General and Administrative expenses rose to approximately $5.2 million for the three months ending December 31, 2025, up from $2.7 million in the same period of 2024, an increase of $2.5 million primarily due to impairment of intangible assets [7]. Corporate Updates - iBio has advanced its preclinical pipeline programs, including IBIO-610 and IBIO-600, towards human clinical trials, with CMC development and toxicology studies initiated [2]. - The company presented new data on IBIO-610 at various industry conferences, indicating a predicted human half-life of up to 100 days, which supports potential dosing as infrequently as twice per year [5]. - The company aims to commence first human clinical trials for IBIO-610 in early calendar year 2027 and enter Phase 1a clinical trials for IBIO-600 in the first half of calendar year 2026 [5][6]. Cash Position - As of December 31, 2025, iBio held cash, cash equivalents, and investments in debt securities totaling $52.7 million, with the recent PIPE financing extending the cash runway into the third quarter of fiscal year 2028 [8].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for iBio, Inc. despite lower revenues, with actual results being crucial for stock price movement [1] Earnings Expectations - iBio is expected to report a quarterly loss of $0.08 per share, reflecting a year-over-year change of +83.3% [3] - Revenues are projected to be $0.1 million, down 50% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 3.45% higher in the last 30 days, indicating a reassessment by analysts [4] - A positive Earnings ESP of +27.27% suggests analysts have become more optimistic about iBio's earnings prospects [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - iBio currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, iBio was expected to post a loss of $0.07 per share but actually reported a loss of -$0.11, resulting in a surprise of -57.14% [13] - Over the past four quarters, iBio has only beaten consensus EPS estimates once [14] Industry Comparison - Bristol Myers Squibb is expected to report an EPS of $1.15 for the same quarter, indicating a year-over-year change of -31.1% [18] - Revenues for Bristol Myers are expected to be $12.25 billion, down 0.7% from the previous year [18] - The consensus EPS estimate for Bristol Myers has been revised down by 3.9% in the last 30 days, and it currently has an Earnings ESP of 0.00% [19][20]